PDT Partners LLC Acquires Shares of 63,859 ADMA Biologics, Inc. (NASDAQ:ADMA)

PDT Partners LLC acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 63,859 shares of the biotechnology company’s stock, valued at approximately $1,277,000.

Several other institutional investors have also recently made changes to their positions in ADMA. Assenagon Asset Management S.A. boosted its holdings in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after buying an additional 80,400 shares in the last quarter. Seven Eight Capital LP purchased a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $1,992,000. Principal Financial Group Inc. boosted its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after buying an additional 1,059,394 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in shares of ADMA Biologics in the third quarter valued at approximately $2,253,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA opened at $20.11 on Monday. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock’s fifty day moving average price is $19.08 and its two-hundred day moving average price is $15.40. The firm has a market cap of $4.75 billion, a PE ratio of 71.82 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the firm earned $0.01 earnings per share. On average, equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on ADMA. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright increased their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.